Human Milk Oligosaccharides (HMOs) for Irritable Bowel Syndrome (IBS)

Not Applicable

Terminated

• Conditions: IBS - Irritable Bowel Syndrome; Irritable Bowel Syndrome
• Interventions: Other: Placebo; Dietary Supplement: Human Milk Oligosaccharide Mix

• Registration Number: NCT05205785
• Lead Sponsor: DSM Nutritional Products, Inc.

Brief Summary

To assess the effects of a Human Milk Oligosaccharide mix given once daily for 12 weeks on stool consistency and abdominal pain compared to placebo in individuals with Irritable Bowel Syndrome (IBS).

Detailed Description

HMO mix has been shown to provide therapeutic benefits to individuals with IBS of all subtypes (Palsson et al., 2019). DSM is planning this trial in order to investigate if clinically relevant improvements in bowel movements and IBS symptoms can be obtained through the use of the HMO mix in individuals with moderate to severe IBS and abdominal pain.

Eligible participants will have a diagnosis of Irritable Bowel Syndrome (IBS). Participants will be assessed for eligibility at the screening visit, must meet all the inclusion criteria, and none of the exclusion criteria.

In this trial, participants will be randomized to one of two intervention groups (a Human Milk Oligosaccharide mix or placebo) and receive intervention for at least 12 weeks.

Study Timeline

• Study First Submitted: 2021-12-22
• Study First Submitted QC: 2022-01-12
• Study First Posted: 2022-01-25
• Study Start: 2023-03-22
• Primary Completion: 2024-03-05
• Study Completion: 2024-06-24
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-05
• Last Update Posted: 2024-08-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 204

Inclusion Criteria

1. Written informed consent obtained before any trial related assessments are performed.

2. Male or female aged ≥18 years at the time of consent.

   a. Female participants of child-bearing potential (females who are post-menopausal, i.e., when there has been no menstruation for a minimum of 12 months prior to screening, are considered not to be of child-bearing potential.), who are not surgically sterilized, must have a negative pregnancy test at screening and be willing to practice one of the following appropriate contraceptive methods until the last visit: i. Sexual abstinence. ii. Oral contraceptives. iii. Trans dermal patches or depot injection of a progestogen drug (starting at least 4 weeks prior to product administration). iv. Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent. v. Intrauterine device (IUD), intrauterine system (IUS), subdermal implant, or vaginal ring (placed at least 4 weeks prior to product administration). vi. Contraceptives must be effective before the randomization visit. However, national requirements should always be followed.

3. IBS-D or IBS-C or IBS-M according to Rome IV criteria. This will be established by using the IBS Module of the Rome IV Diagnostic Questionnaire, and requires recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following:

   1. Related to defecation (may be increased or unchanged by defecation) on at least 30% of pain instances in past 3 months.
   2. Associated with a change in stool frequency (on at least 30% of pain instances in past 3 months).
   3. Associated with a change in stool form or appearance (on at least 30% of pain instances in past 3 months).

4. Reported IBS diagnosis from a physician.

5. Personal access to the internet via computer, tablet, or smart-phone.

6. Be willing and able to comply with trial protocol, including entry of electronic diary data for at least 12 out of 14 diary days during the pre-randomization baseline 2-week run-in diary period (between V1 andV2).

   Inclusion criteria Visit 2: To be eligible for inclusion, the participant must fulfil all of the following criteria:

7. Scores of 1, 2, 6, or 7 on the Bristol stool scale at least twice per week [as determined by eDiary completion between V1 and V2].

8. An average baseline of worst abdominal pain of ≥3.3 (NRS-11) during the 2-week run-in period prior to randomization [as determined by eDiary completion between V1 and V2].

Exclusion Criteria

The presence of any of the following criteria will exclude the participant from participating in the trial:

1. Treatment with an investigational drug from another clinical trial within 30 days/5 half- lives of the drug (which ever longest) prior to screening visit.

2. Any known gastrointestinal disease(s) or medical history that may interfere with the trial evaluations in the opinion of the investigator, in particular:

   1. Coeliac disease.
   2. IBD.
   3. Diverticulitis.
   4. C. difficile infection reported in the previous 2 years.
   5. Any clinically symptomatic biochemical or structural abnormality or active disease of the gastrointestinal tract within 6 months before screening, including daily diarrhea within two weeks prior to the screening interview or during the screening/baseline period.
   6. Substance abuse (within past 2 years).
   7. New use of antibiotics (within past 2 months), prebiotics, probiotics, or fiber supplements (within the past month).
   8. Hepatic dysfunction assessed as part of the blood safety panel (defined as alanine aminotransaminase/serum glutamic-pyruvic transaminase or aspartate aminotransaminase/serum glutamic-oxaloacetic transaminase >2.5 x the upper limit of normal, or a history of hepatobiliary disease) or renal impairment (serum creatinine) >2 mg/dl); any surgery (within a year of screening) on the stomach, small intestine, or colon (excluding appendectomy, hernia surgery not involving the GI tract, or c-section).
   9. Any history of pancreatitis (either acute or chronic).
   10. Laxative abuse (use of more than recommended dosage).
   11. Pregnant or lactating individuals.
   12. Any other gastrointestinal disease(s) or medical history that may interfere with the trial evaluations in the judgment of the investigator.

3. Following strict diets to improve their IBS symptoms as judged by the investigator e.g., Low FODMAP (within past 2 months). Exclusion based on diet will be reviewed by single investigator for consistency.

4. Any clinically relevant chronic disease(s) such as malignancy, diabetes, severe coronary disease, kidney disease, autoimmune or neurological disease, that in the opinion of the investigator would interfere with the trial evaluations or the safety of the participant.

5. Current severe psychiatric disease and/or psychological disturbance, a major psychiatric disorder requiring hospitalization in the last 3 years, or a history of attempted suicide or uncontrolled bipolar disorder; or clinical evidence of any significant psychiatric disease or symptoms that may interfere with the participant successfully completing the trial.

6. Treatment with restricted and prohibited concomitant medications.

7. Diagnosed with and treated for IBS for more than 10 years

8. Has a business or personal relationship with trial staff or sponsor who is directly involved with the conduct of the trial.

9. Lack of suitability for participation in the study for any reason as judged by the investigator.

10. Has previously been randomized into this trial, is participating in this trial at another investigational site or is planning to participate in any other clinical trial during this trial.

11. Desire and/or plans on changing current diet regime during the participation of this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	The placebo to be used in this trial is 5.5 g of powdered dextrose powder in a single-serve stick pack. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.
Human Milk Oligosaccharide (HMO) mix	Human Milk Oligosaccharide Mix	The HMO blend to be used in this trial is a mix of the three milk oligosaccharides produced by fermentation of lactose. The blend is provided as white powder and mixed in a single serve stick packs containing 5.5 g of HMOs. The final product contains less than 0.03 g lactose per serving. The participants will be instructed to mix the product in a 4-6 oz glass of water and consume in the morning once a day for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Absolute change in the pain severity score (IBS-SSS) in the active product compared to placebo group.	Baseline (Visit 2) to Week 12 (Visit 3)	The IBS Symptom Severity Scale (IBS-SSS) contains a pain subscale which asks participants to rate abdominal pain the past 10 days on a scale from 0 to 100, with 0 meaning "no pain" and 100 meaning "very severe pain". The minimum score is 0 and the maximum achievable score is 100.
Absolute change in the proportion of stools with abnormal fecal consistency in the active product compared to placebo group.	Baseline (2 week run in period) to end of intervention (weeks 11 + week 12)	Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass \[classified as severe constipation\]; Type 7 = watery, entirely liquid stool \[classified as severe diarrhea\]). Types 1 and 2 would be considered to suggest severe and mild diarrhea, respectively. Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively. This endpoint will compare the proportion of participants experiencing constipation and diarrhea between the groups

Secondary Outcome Measures

Name	Time	Method
Absolute change in total IBS severity score in the active product compared to placebo group.	Baseline (Visit 2) to Week 12 (Visit 3)	The IBS Symptom Severity Scale (IBS-SSS) contains 5 items. Each of the five questions generate a maximum score of 100 using prompted visual analogue scales. The minimum score is 0 and the maximum achievable score is 500.
Relative change in abundance of fecal Bifidobacteria spp in the active product compared to placebo group.	Baseline (Visit 2) to Week 12 (Visit 3)	Relative change in abundance measured by gene sequencing analysis of fecal sample.
Absolute change in total IBS Quality of Life (IBS-QOL) score in the active product compared to placebo group.	Baseline (Visit 2) to Week 12 (Visit 3)	The IBS Quality of Life contains 34 items each with a five-point response scale, where 1 represents not at all and 5 extremely/A great detail. The participant ill answer each question with respect to the impact of IBS and it's treatment. The individual responses to the 34 items are summed and averaged for a total score and transformed to a 0-100 scale for interpretation with higher scores indicating better IBS specific quality of life.

Trial Locations

Locations (1)

Atlantia Clinical Trials Ltd; 🇮🇪 Cork, Cork/Munster, Ireland